| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $622,448 ) |
| | 2025 | 2025 | TRETHERA CORP | 13451 RAND DR | SHERMAN OAKS | CA | 91423-4807 | LOS ANGELES | USA | R42EY034397 | Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Optic Neuritis | 001 | 3 | NIH | 2/14/2025 | $622,448 |
| | 2025 | 2022 | TRETHERA CORP | 13451 RAND DR | SHERMAN OAKS | CA | 91423-4807 | LOS ANGELES | USA | R42EY034397 | Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Optic Neuritis | 000 | 1 | NIH | 1/15/2025 | $0 |
|
| Issue Date FY: 2024 ( Subtotal = $2,965,289 ) |
| | 2024 | 2024 | TRETHERA CORP | 13451 RAND DR | SHERMAN OAKS | CA | 91423-4807 | LOS ANGELES | USA | R44CA281485 | Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleotide Salvage Pathway to Treat Underserved Tumor Types | 000 | 2 | NIH | 5/22/2024 | $696,570 |
| | 2024 | 2024 | TRETHERA CORP | 13451 RAND DR | SHERMAN OAKS | CA | 91423-4807 | LOS ANGELES | USA | R41AI179213 | Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Systemic Lupus Erythematosus | 000 | 2 | NIH | 5/14/2024 | $305,715 |
| | 2024 | 2024 | TRETHERA CORP | 13451 RAND DR | SHERMAN OAKS | CA | 91423-4807 | LOS ANGELES | USA | R44AI186534 | Development of a novel, targeted small molecule inhibitor of the nucleoside salvage pathway through IND enabling studies and translational mouse models for acute disseminated encephalomyelitis (ADEM) | 000 | 1 | NIH | 7/2/2024 | $1,050,000 |
| | 2024 | 2024 | TRETHERA CORP | 13451 RAND DR | SHERMAN OAKS | CA | 91423-4807 | LOS ANGELES | USA | R41AI179191 | Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Acute Disseminated Encephalomyelitis (ADEM) | 000 | 2 | NIH | 7/5/2024 | $297,146 |
| | 2024 | 2024 | TRETHERA CORP | 13451 RAND DR | SHERMAN OAKS | CA | 91423-4807 | LOS ANGELES | USA | R42EY034397 | Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Optic Neuritis | 001 | 2 | NIH | 2/8/2024 | $615,858 |
| | 2024 | 2022 | TRETHERA CORP | 13451 RAND DR | SHERMAN OAKS | CA | 91423-4807 | LOS ANGELES | USA | R42EY034397 | Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Optic Neuritis | 000 | 1 | NIH | 2/7/2024 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $2,354,520 ) |
| | 2023 | 2023 | TRETHERA CORP | 13451 RAND DR | SHERMAN OAKS | CA | 91423-4807 | LOS ANGELES | USA | R44CA281485 | Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleotide Salvage Pathway to Treat Underserved Tumor Types | 000 | 1 | NIH | 5/30/2023 | $1,349,805 |
| | 2023 | 2023 | TRETHERA CORP | 13451 RAND DR | SHERMAN OAKS | CA | 91423-4807 | LOS ANGELES | USA | R41DK138578 | Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Crohn's disease | 000 | 1 | NIH | 9/19/2023 | $395,119 |
| | 2023 | 2023 | TRETHERA CORP | 13451 RAND DR | SHERMAN OAKS | CA | 91423-4807 | LOS ANGELES | USA | R41AI179191 | Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Acute Disseminated Encephalomyelitis (ADEM) | 000 | 1 | NIH | 7/31/2023 | $304,461 |
| | 2023 | 2023 | TRETHERA CORP | 13451 RAND DR | SHERMAN OAKS | CA | 91423-4807 | LOS ANGELES | USA | R41AI179213 | Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Systemic Lupus Erythematosus | 000 | 1 | NIH | 6/21/2023 | $305,135 |
|
| Issue Date FY: 2022 ( Subtotal = $368,195 ) |
| | 2022 | 2022 | TRETHERA CORPORATION | 13451 RAND DR | SHERMAN OAKS | CA | 91423 | LOS ANGELES | USA | R42EY034397 | Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Optic Neuritis | 000 | 1 | NIH | 9/15/2022 | $368,195 |
|
|
